Dr. Ibrahim A. Ahmed
Claim this profileChildren's Mercy Hospital
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
5 reported clinical trials
8 drugs studied
Area of expertise
1Leukemia
NGS-MRD negative
HLA negative
RB1 positive
2Lymphoblastic Leukemia-Lymphoma
NGS-MRD negative
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Ibrahim A. Ahmed is currently running
Non-TBI Conditioning
for HCT in Acute Lymphoblastic Leukemia
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be followed in an observational cohort (HCT center standard of care).
Recruiting1 award Phase 2
Stem Cell Transplant Conditioning
for SCID
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
Recruiting1 award Phase 244 criteria
More about Ibrahim A. Ahmed
Clinical Trial Related6 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Ibrahim A. Ahmed has experience with
- Myeloablative Allogeneic HCT With A Non-TBI Conditioning Regimen
- NGS-MRD
- Busulfan
- Cell Processing For TCRαβ+/CD19+ Depletion
- Donor Search Prognosis Score
- Lactobacillus Plantarum
Breakdown of trials Ibrahim A. Ahmed has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Lymphoma
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ibrahim A. Ahmed specialize in?
Ibrahim A. Ahmed focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved NGS-MRD negative patients, or patients who are HLA negative.
Is Ibrahim A. Ahmed currently recruiting for clinical trials?
Yes, Ibrahim A. Ahmed is currently recruiting for 3 clinical trials in Kansas City Missouri. If you're interested in participating, you should apply.
Are there any treatments that Ibrahim A. Ahmed has studied deeply?
Yes, Ibrahim A. Ahmed has studied treatments such as Myeloablative allogeneic HCT with a non-TBI conditioning regimen, NGS-MRD, Busulfan.
What is the best way to schedule an appointment with Ibrahim A. Ahmed?
Apply for one of the trials that Ibrahim A. Ahmed is conducting.
What is the office address of Ibrahim A. Ahmed?
The office of Ibrahim A. Ahmed is located at: Children's Mercy Hospital, Kansas City, Missouri 64108 United States. This is the address for their practice at the Children's Mercy Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.